An in vivo genome-wide CRISPR identifies a key regulator of myeloid leukemia

2020-07-20 08:12

RNA-binding proteins play important roles in maintaining drug resistance of leukemia. In a recent research, team of Dr. Tannishtha Reya from University of California San Diego revealed that the double-stranded RNA-binding protein Staufen2 is a key regulator of myeloid leukemia.

In April.2020, they demonstrated the research result in Nature Cancer, that by deleting Stau2 gene in mice using CRISPR technology, the development of myeloid malignancies is affected, and the survival rate of mice dramatically increases.

Dr. Tannishtha Reya described that they screen thousands of gene using powerful CRISPR technology, which helps them recognize genes promoting the development of leukemia. These data shows the great effectiveness of in vivo CRISPR screening for defining the regulators of myeloid leukemia progression.



References:Bajaj J , Hamilton M , Shima Y , et al. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia[J]. Nature Cancer, 2020.